




# Pharmacological agents to prevent recurrent *C. diff* infection (20150362)

**Cholic and bile acid derivatives that inhibit *Clostridium difficile* spore germination to prevent or treat *C. diff* infection.**



**IP Status:** US Patent Pending; **Application #:** 15/998,547

## Applications

- *C. diff* prevention and/or treatment
- Alternative to antibiotics or fecal microbiota transplantation (FMT)
- Hospitals
- Oral therapeutics

## Benefits

- Could prevent, treat, and/or reduce risk of developing a *Clostridium*-associated infection
- Will not kill useful and necessary microorganisms (microbiota)
- Remains stable in acidic stomach environment
- Avoids reuptake into the enterohepatic circulation in the colon

## Features

- Cholic and bile acid derivatives
- Therapeutic compounds inhibit taurocholate-induced spore germination
- Offers a non-antibiotic alternative to treating *C. diff*
- May replace FMT (fecal microbiota transplant) therapy
- Resistant to 7α-dehydroxylation by colonic flora

## Inhibits *C. diff* germination to prevent and treat infection

Newly developed cholic and bile acid derivatives could inhibit *Clostridium difficile* spore germination, which could prevent, treat, and/or reduce the risk of developing *Clostridium*-associated infections. The therapeutic compounds inhibit taurocholate-induced spore germination. They are expected to remain stable under highly acidic conditions (such as those in the stomach), to avoid reuptake into the liver and to remain resistant to 7α-dehydroxylation by colonic flora. The antigermnants should prevent germination of *Clostridium difficile* spores and could be used to prevent and treat *C. diff* infections.

**Technology ID**

20150362

## Category

Life Sciences/Biochemicals & Small Molecules

Life Sciences/Human Health

Life Sciences/Pharmaceuticals

Life Sciences/Therapeutics

Agriculture &

Veterinary/Veterinary Medicine

## Learn more



## No antibiotics or fecal microbial transplant (FMT) required

Bile acids produced in the gallbladder are able to inhibit germination of *Clostridium difficile* spores, but orally dosed bile acids do not reach the large intestine in large enough quantities to be effective. Several reasons are responsible: they break down in the stomach, reuptake receptors pull them from the gut, and/or bacterial enzymes break them down. Standard *C. difficile* treatments use antibiotics that disrupt indigenous microbiota and often fail to eradicate bacterial spores, increasing recurrence of infection. These newly developed bile acid derivatives could replace secondary bile acids or their analogues inhibitory to *C. diff*. Because germination in the human colon is critical in *C. diff* pathogenesis, these novel pharmaceuticals could treat this disease, particularly in patients who have had multiple rounds of antibiotic treatment with no results. With further development, the drug candidates could replace currently available treatments and provide an antibiotic-free option that does not require fecal microbial transplant (FMT).

## Phase of Development

- In Vitro assessment.

## Desired Partnerships

This technology is now available for:

- License
- Sponsored research
- Co-development

Please contact our office to share your business' needs and learn more.

## Researchers

- [Alex Khoruts, MD](#) Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition
- [Michael Sadowsky, PhD](#) Professor, Department of Microbiology and Immunology
- [Peter Dosa, PhD](#) Associate Program Director, Medicinal Chemistry, Institute for Therapeutics Discovery and Development (ITDD)
- [Clifford Steer, MD](#) Professor of Medicine, Division of Gastroenterology Hepatology and Nutrition

## References

1. Kristen L. Stoltz et al.(2017) , <https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00295>, Journal of Medicinal Chemistry, 60(8), 3451-3471
2. Peter I. Dosa et al.(2013) , <https://experts.umn.edu/en/publications/synthesis-and-evaluation-of-water-soluble-prodrugs-of-ursodeoxych>, ChemMedChem, 8, 1002-1011